Castle Biosciences

CSTL · NASDAQ

$33.15+$0.985 (+3.06%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $32.17

CSTL analyst rating

BuyConsensus of 6 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy6
Hold0
Underperform0
Sell0

12-month price target · 11 analysts

Average $46.01 (+38.8% upside)

Low: $35.35
Now: $33.15
High: $59.85

Upgrades and downgrades

The latest rating actions, newest first

CSTL analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
BTIG	Aug 3, 2026	Maintains	Buy	$40.00 → $44.00	54%
Roth Capital	Jun 25, 2026	Initiates	Buy	$40.00	36%
BTIG	May 13, 2026	Maintains	Buy	$50.00 → $40.00	54%
Baird	May 7, 2026	Maintains	Outperform	$44.00 → $43.00	59%
Canaccord Genuity	Apr 20, 2026	Maintains	Buy	$50.00 → $40.00	55%
Baird	Feb 27, 2026	Maintains	Outperform	$41.00 → $44.00	59%
Guggenheim	Jan 26, 2026	Maintains	Buy	$43.00 → $47.00	66%
Lake Street	Jan 12, 2026	Maintains	Buy	$35.00 → $52.00	27%
Guggenheim	Jan 5, 2026	Maintains	Buy	$30.00 → $43.00	66%
Canaccord Genuity	Dec 22, 2025	Maintains	Buy	$37.00 → $50.00	55%

The case for and against

Updated Feb 9, 2026

Bull case

Castle Biosciences Inc. has demonstrated significant growth in its TissueCypher test, with test volume increasing by 92% year-over-year and 23% quarter-over-quarter in the second quarter of 2025, indicating strong market demand and effective sales force expansion. The company has also successfully improved the gross margin for the TissueCypher test, reporting an impressive 77% in the third quarter, which reflects operational efficiencies and profitability potential. With most of the gastrointestinal sales force expected to reach maturity in the second half of 2025, the outlook for continued revenue growth in this segment appears optimistic.

Bear case

Castle Biosciences Inc. faces a challenging outlook as its EV-to-estimated 2026/2027 revenue multiples for its dermatology and DecisionDx-UM tests are projected to be significantly lower than those for TissueCypher, indicating potential revenue pressures. A lack of clinician awareness, particularly within the gastroenterology sector, is identified as a major roadblock, suggesting that the company is struggling to penetrate the market effectively. Despite indications that the stock is undervalued from a conservative perspective, the fundamental concerns around market penetration and revenue generation raise doubts about its growth potential in the near term.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.